Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
474.5 USD | +0.89% | +1.23% | +16.61% |
02/07 | FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis | MT |
02/07 | Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.61% | 121B | |
+17.75% | 110B | |
+17.23% | 25.98B | |
-24.11% | 19.27B | |
-18.56% | 15.99B | |
-18.47% | 15.66B | |
-47.75% | 14.5B | |
+57.35% | 14.47B | |
+5.62% | 13.91B | |
+125.88% | 10B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis